Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR Variations in Concurrent TP53 Mutations Research Summary
This trial compared the efficacy and safety of osimertinib + chemotherapy vs osimertinib alone in patients with epidermal growth factor receptor (EGFR)–mutated advanced non–small cell lung cancer (NSCLC) harboring TP53 mutations.
